These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 18573136)
1. Beyond anemia: the clinical impact of the physiologic effects of erythropoietin. Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB Semin Dial; 2008; 21(5):447-54. PubMed ID: 18573136 [TBL] [Abstract][Full Text] [Related]
2. [The clinical impact of the physiological effects of erythropoietin and erythropoietin-stimulating agents on the incidence of malignancy, and hypertension: beyond anaemia]. Ortega LM; Contreras G Nefrologia; 2009; 29(4):288-94. PubMed ID: 19668298 [TBL] [Abstract][Full Text] [Related]
3. [Erythropoietin: indications and measurement]. Klein E; Georges A; Brossaud J; Bosredon Kd; Bordenave L; Corcuff JB Ann Biol Clin (Paris); 2009; 67(5):505-15. PubMed ID: 19789122 [TBL] [Abstract][Full Text] [Related]
11. Erythropoietin-induced hypertension. Ismail N; Ikizler TA J Med Liban; 1997; 45(1):25-30. PubMed ID: 9421942 [No Abstract] [Full Text] [Related]
12. Erythropoietin resistance in the treatment of the anemia of chronic renal failure. Priyadarshi A; Shapiro JI Semin Dial; 2006; 19(4):273-8. PubMed ID: 16893403 [TBL] [Abstract][Full Text] [Related]
13. Cellular protection by erythropoietin: new therapeutic implications? Joyeux-Faure M J Pharmacol Exp Ther; 2007 Dec; 323(3):759-62. PubMed ID: 17717190 [TBL] [Abstract][Full Text] [Related]
14. Anemia in chronic heart failure: etiology and treatment options. Westenbrink BD; de Boer RA; Voors AA; van Gilst WH; van Veldhuisen DJ Curr Opin Cardiol; 2008 Mar; 23(2):141-7. PubMed ID: 18303527 [TBL] [Abstract][Full Text] [Related]
15. [The cardiorenal syndrome and erythropoietin]. Kes P; Basić-Jukić N; Jurić I; Basić-Kes V Acta Med Croatica; 2008; 62 Suppl 1():21-31. PubMed ID: 18578329 [TBL] [Abstract][Full Text] [Related]